- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.03. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering | 1 | GlobeNewswire (USA) | ||
| 12.03. | Shuttle Pharma ernennt neuen Interims-Co-CEO | 2 | Investing.com Deutsch | ||
| 12.03. | Shuttle Pharma appoints new interim co-CEO | 1 | Investing.com | ||
| 12.03. | Shuttle Pharmaceuticals appoints Christopher Cooper as interim co-CEO | 1 | Seeking Alpha | ||
| SHUTTLE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.03. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities | 106 | GlobeNewswire (Europe) | GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical... ► Artikel lesen | |
| 12.03. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.03. | Shuttle Pharmaceuticals Holdings, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 27.02. | Shuttle Pharmaceuticals reports FY results | 1 | Seeking Alpha | ||
| 26.02. | Shuttle Pharma macht Fortschritte bei Glioblastom-Studie und erweitert Diagnostik | - | Investing.com Deutsch | ||
| 26.02. | Shuttle Pharma advances glioblastoma trial, expands diagnostics | 1 | Investing.com | ||
| 26.02. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate Update and Reports 2024 Results | 174 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical... ► Artikel lesen | |
| 26.02. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.02. | Shuttle Pharmaceuticals Holdings, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 13.02. | Shuttle Pharmaceuticals Holdings, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 28.01. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.01. | Shuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma | 129 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused... ► Artikel lesen | |
| 21.01. | Shuttle Pharma hits 25% mark in glioblastoma trial | 1 | Investing.com | ||
| 21.01. | Shuttle Pharmaceuticals Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.01. | Shuttle Pharmaceuticals Holdings, Inc. - S-1, General form for registration of securities | - | SEC Filings |
Seite:
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 0,123 | +2,93 % | Breaking News: Patent-Meldung beflügelt InnoCan Pharma?! | ||
| CRESCO LABS | 0,514 | +2,09 % | Cresco Labs Aktie: Komplexe Lage droht? | Cresco Labs verzeichnete im Geschäftsjahr 2024 eine beeindruckende finanzielle Entwicklung mit einem Jahresumsatz von 724 Millionen Euro. Trotz dieser positiven Kennzahlen schloss das Unternehmen mit... ► Artikel lesen | |
| CSPC PHARMA | 0,563 | +0,90 % | CSPC PHARMA (01093): NEXT DAY DISCLOSURE RETURNS | ||
| TONIX PHARMACEUTICALS | 18,000 | -0,11 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting | TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant improvement... ► Artikel lesen | |
| AMARIN | 0,382 | -1,55 % | Amarin adds investment expert Michael Torok to Board | ||
| NEKTAR THERAPEUTICS | 0,428 | -5,23 % | NEKTAR THERAPEUTICS - 8-K, Current Report | ||
| JAGUAR HEALTH | 4,920 | 0,00 % | Jaguar Health, Inc.: Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product | Gelclair® is the company's third commercialized prescription productOral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,800 | +0,25 % | XORTX gibt Update zu Gesprächen mit der FDA bekannt | - Gespräche im Rahmen eines Typ-B-Meetings für ein verkürztes NDA-Zulassungsverfahren für XRx-026 zur Gichtbehandlung
CALGARY, ALBERTA, den 19. März 2025 / IRW-Press / XORTX... ► Artikel lesen | |
| NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA LR23: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUMINUS WELLNESS... ► Artikel lesen | |
| CANNOVUM CANNABIS | 0,180 | -32,08 % | EQS-News: Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich | EQS-News: Cannovum Cannabis AG
/ Schlagwort(e): Strategische Unternehmensentscheidung/Sonstiges
Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich... ► Artikel lesen | |
| TALPHERA | 0,456 | +1,33 % | Talphera, Inc.: Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70
Talphera expects the registrational NEPHRO... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,044 | -8,42 % | BetterLife Pharma Inc. - 6-K, Report of foreign issuer | ||
| MEDIPHARM LABS | 0,054 | -4,96 % | MediPharm Labs Corp.: MediPharm Labs Reports Full Year & Fourth Quarter 2024 Results | Annual Net Revenue Increase of 27% to $42M, Driven by Record $18M International Medical Cannabis Revenue and Approaching Positive Adjusted EBITDA(1) for Q4. TORONTO, March 31, 2025 /PRNewswire/... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,009 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SCYNEXIS | 0,750 | +3,02 % | SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update | The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted... ► Artikel lesen |
Das Unternehmen SHUTTLE PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -8,54 % bei einem Aktienkurs von 0,407 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHUTTLE PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.
